328 related articles for article (PubMed ID: 27646474)
1. iRGD-mediated core-shell nanoparticles loading carmustine and O
Liu C; Yao S; Li X; Wang F; Jiang Y
J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474
[TBL] [Abstract][Full Text] [Related]
2. Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
Qian L; Zheng J; Wang K; Tang Y; Zhang X; Zhang H; Huang F; Pei Y; Jiang Y
Biomaterials; 2013 Nov; 34(35):8968-78. PubMed ID: 23953782
[TBL] [Abstract][Full Text] [Related]
3. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
4. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
6. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
7. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
[TBL] [Abstract][Full Text] [Related]
8. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma.
Pang L; Qin J; Han L; Zhao W; Liang J; Xie Z; Yang P; Wang J
Oncotarget; 2016 Jun; 7(24):37081-37091. PubMed ID: 27213597
[TBL] [Abstract][Full Text] [Related]
9. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth.
Gao H; Yang Z; Zhang S; Cao S; Pang Z; Yang X; Jiang X
J Control Release; 2013 Dec; 172(3):921-8. PubMed ID: 24120853
[TBL] [Abstract][Full Text] [Related]
10. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
[TBL] [Abstract][Full Text] [Related]
11. Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles.
Chu Y; Chen N; Yu H; Mu H; He B; Hua H; Wang A; Sun K
Int J Nanomedicine; 2017; 12():1353-1368. PubMed ID: 28260884
[TBL] [Abstract][Full Text] [Related]
12. Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
Guo X; Wu G; Wang H; Chen L
J Pharm Sci; 2019 May; 108(5):1726-1735. PubMed ID: 30537472
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
Kang C; Yuan X; Zhong Y; Pu P; Guo Y; Albadany A; Yu S; Zhang Z; Li Y; Chang J; Sheng J
Technol Cancer Res Treat; 2009 Feb; 8(1):61-70. PubMed ID: 19166243
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
15. Development and in vitro evaluation of carmustine delivery platform: A hypoxia-sensitive anti-drug resistant nanomicelle with BBB penetrating ability.
Li D; Ren T; Wang X; Xiao Z; Sun G; Zhang N; Zhao L; Zhong R
Biomed Pharmacother; 2023 Nov; 167():115631. PubMed ID: 37804814
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration.
Dai J; Han S; Ju F; Han M; Xu L; Zhang R; Sun Y
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):860-873. PubMed ID: 29771149
[TBL] [Abstract][Full Text] [Related]
18. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
Kang T; Gao X; Hu Q; Jiang D; Feng X; Zhang X; Song Q; Yao L; Huang M; Jiang X; Pang Z; Chen H; Chen J
Biomaterials; 2014 May; 35(14):4319-32. PubMed ID: 24565520
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting DVDMS-nanoliposomes for an enhanced sonodynamic therapy of gliomas.
Sun Y; Wang H; Wang P; Zhang K; Geng X; Liu Q; Wang X
Biomater Sci; 2019 Feb; 7(3):985-994. PubMed ID: 30601475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
